Start main content

PD1-Based TWIST1 Cancer Vaccine

PD1-Based TWIST1 Cancer Vaccine
Therapeutic Biologics
Reference No.

Key Problem and Market Opportunity

Figure 1. Checkpoint Modulation Enhances the Antitumor Activity of sPD1-TWIST1 Vaccination for Curing Established Mesothelioma
Figure 2. Combination Therapy Induced Durable T Cell Immunity Responsive to an Immunodominant TWIST1 Epitope

Key Advantages of the Technology

  • Eliciting long-term memory CD8+ T responses against tumors.
  • Demonstrated efficacy in treating mesothelioma and breast cancer

Potential Product and Services

Cancer vaccines that enhance immunotherapy against tumors

Development Status

  • US Provisional Application No. 62/978,911
IP Status
  • Patent application submitted

Work with us